Show simple item record

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines : an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

dc.contributor.authorToback, Seth
dc.contributor.authorGaliza, Eva
dc.contributor.authorCosgrove, Catherine
dc.contributor.authorGalloway, James
dc.contributor.authorGoodman, Anna L
dc.contributor.authorSwift, Pauline A
dc.contributor.authorRajaram, Sankarasubramanian
dc.contributor.authorGraves-Jones, Alison
dc.contributor.authorEdelman, Jonathan
dc.contributor.authorBurns, Fiona
dc.contributor.authorMinassian, Angela M
dc.contributor.authorCho, Iksung
dc.contributor.authorKumar, Lakshmi
dc.contributor.authorPlested, Joyce S
dc.contributor.authorRivers, E Joy
dc.contributor.authorRobertson, Andreana
dc.contributor.authorDubovsky, Filip
dc.contributor.authorGlenn, Greg
dc.contributor.authorHeath, Paul T
dc.contributor.author2019nCoV-302 Study Group
dc.date.accessioned2023-10-04T23:07:44Z
dc.date.available2023-10-04T23:07:44Z
dc.date.issued2022-02-01
dc.identifier209050084
dc.identifier2acc30be-483b-4da0-b300-4c85ae30002e
dc.identifier34800364
dc.identifier85115229638
dc.identifier.citationToback , S , Galiza , E , Cosgrove , C , Galloway , J , Goodman , A L , Swift , P A , Rajaram , S , Graves-Jones , A , Edelman , J , Burns , F , Minassian , A M , Cho , I , Kumar , L , Plested , J S , Rivers , E J , Robertson , A , Dubovsky , F , Glenn , G , Heath , P T & 2019nCoV-302 Study Group 2022 , ' Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines : an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial ' , The Lancet. Respiratory medicine , vol. 10 , no. 2 , pp. 167-179 . https://doi.org/10.1016/S2213-2600(21)00409-4en
dc.identifier.issn2213-2600
dc.identifier.otherORCID: /0000-0002-1397-4272/work/126282681
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/19826
dc.descriptionFunding Novavax. Acknowledgments This study was funded by Novavax. Editorial assistance in the preparation of this manuscript was provided by Phase Five Communications, funded by Novavax. We thank all the study participants for their commitment to this study. We also acknowledge the investigators and their study teams for their hard work and dedication. In addition, we thank the National Institute for Health Research (NIHR) Clinical Research Network, the NIHR Oxford Cognitive Health Clinical Research Facility, NHS Digital, and the UK Vaccine Task Force; and we are grateful to the Wellcome Trust funding for the Northern Ireland Clinical Research Facility.en
dc.format.extent13
dc.format.extent7242123
dc.language.isoeng
dc.relation.ispartofThe Lancet. Respiratory medicineen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleSafety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines : an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1016/S2213-2600(21)00409-4
dc.date.embargoedUntil2022-05-17
dc.identifier.vol10en
dc.identifier.iss2en


Files in this item

Thumbnail
Name:
Paoli_etal_CO_Another_Brick_In ...
Size:
246.5Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record